Cargando…

Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target

Despite the remarkable success of immune checkpoint inhibitors (ICIs) in melanoma treatment, resistance to them remains a substantial clinical challenge. Myeloid-derived suppressor cells (MDSCs) represent a heterogeneous population of myeloid cells that can suppress antitumor immune responses mediat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ozbay Kurt, Feyza Gul, Lasser, Samantha, Arkhypov, Ihor, Utikal, Jochen, Umansky, Viktor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313369/ https://www.ncbi.nlm.nih.gov/pubmed/37395271 http://dx.doi.org/10.1172/JCI170762

Ejemplares similares

Melanoma patients with immune-related adverse events after immune checkpoint inhibitors are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCs
por: Lepper, Alisa, et al.
Publicado: (2023)

HSP90α induces immunosuppressive myeloid cells in melanoma via TLR4 signaling
por: Arkhypov, Ihor, et al.
Publicado: (2022)

Myeloid Cell Modulation by Tumor-Derived Extracellular Vesicles
por: Arkhypov, Ihor, et al.
Publicado: (2020)

Blocking Migration of Polymorphonuclear Myeloid-Derived Suppressor Cells Inhibits Mouse Melanoma Progression
por: Groth, Christopher, et al.
Publicado: (2021)

Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma
por: Petrova, Vera, et al.
Publicado: (2020)

Booster dose of mRNA vaccine augments waning T cell and antibody responses against SARS-CoV-2
por: Özbay Kurt, Feyza Gül, et al.
Publicado: (2022)

The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression
por: Umansky, Viktor, et al.
Publicado: (2016)

STAT3 inhibitor Napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing mice
por: Bitsch, Rebekka, et al.
Publicado: (2022)

Immunosuppressive capacity of circulating MDSC predicts response to immune checkpoint inhibitors in melanoma patients
por: Petrova, Vera, et al.
Publicado: (2023)

Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression
por: Groth, Christopher, et al.
Publicado: (2018)

Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression
por: Fleming, Viktor, et al.
Publicado: (2018)

Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
por: Weber, Rebekka, et al.
Publicado: (2018)

HER3-Receptor-Mediated STAT3 Activation Plays a Central Role in Adaptive Resistance toward Vemurafenib in Melanoma
por: Hüser, Laura, et al.
Publicado: (2020)

Myeloid-Derived Suppressor Cells Interact with Tumors in Terms of Myelopoiesis, Tumorigenesis and Immunosuppression: Thick as Thieves
por: Sevko, Alexandra, et al.
Publicado: (2012)

Leukocyte Count Restoration Under Dabrafenib Treatment in a Melanoma Patient With Vemurafenib-Induced Leukopenia: Case Report
por: Orouji, Elias, et al.
Publicado: (2014)

New strategies for melanoma immunotherapy: How to overcome immunosuppression in the tumor microenvironment
por: Umansky, Viktor
Publicado: (2012)

Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy
por: Tomela, Katarzyna, et al.
Publicado: (2023)

Melanoma-Derived iPCCs Show Differential Tumorigenicity and Therapy Response
por: Bernhardt, Mathias, et al.
Publicado: (2017)

Targeting Myeloid-Derived Suppressor Cells in Cancer Immunotherapy
por: Wang, Yufei, et al.
Publicado: (2020)

Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy
por: Hao, Zhaonian, et al.
Publicado: (2021)

Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
por: Bronte, Vincenzo, et al.
Publicado: (2016)

ADCK2 Knockdown Affects the Migration of Melanoma Cells via MYL6
por: Vierthaler, Marlene, et al.
Publicado: (2022)

Correction to: Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy
por: Hao, Zhaonian, et al.
Publicado: (2022)

Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy
por: Krishnamoorthy, Mithunah, et al.
Publicado: (2021)

Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy
por: Wu, Yuze, et al.
Publicado: (2022)

Mithramycin A and Mithralog EC-8042 Inhibit SETDB1 Expression and Its Oncogenic Activity in Malignant Melanoma
por: Federico, Aniello, et al.
Publicado: (2020)

IL-6 regulates CCR5 expression and immunosuppressive capacity of MDSC in murine melanoma
por: Weber, Rebekka, et al.
Publicado: (2020)

Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy
por: Joshi, Shweta, et al.
Publicado: (2022)

Myeloid-derived suppressor cells and the efficacy of CD8(+) T-cell immunotherapy
por: Lesokhin, Alexander M., et al.
Publicado: (2013)

Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment
por: Gao, Xidan, et al.
Publicado: (2021)

Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies
por: Wagner, Nikolaus B., et al.
Publicado: (2019)

Neutrophils in Tumorigenesis: Missing Targets for Successful Next Generation Cancer Therapies?
por: Tolle, Fabrice, et al.
Publicado: (2021)

Myeloid-Derived Suppressor Cells and Therapeutic Strategies in Cancer
por: Katoh, Hiroshi, et al.
Publicado: (2015)

Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors
por: Simon, Sonja C. S., et al.
Publicado: (2020)

Deciphering myeloid-derived suppressor cells: isolation and markers in humans, mice and non-human primates
por: Cassetta, Luca, et al.
Publicado: (2019)

Myeloid derived suppressor cells—An overview of combat strategies to increase immunotherapy efficacy
por: Draghiciu, Oana, et al.
Publicado: (2015)

Role of myeloid-derived suppressor cells in the promotion and immunotherapy of colitis-associated cancer
por: Wang, Yungang, et al.
Publicado: (2020)

Myeloid-Derived Suppressor Cells in Kidney Transplant Recipients and the Effect of Maintenance Immunotherapy
por: Iglesias-Escudero, María, et al.
Publicado: (2020)

Increased Frequency of Myeloid-Derived Suppressor Cells in Myasthenia Gravis After Immunotherapy
por: Wang, Yan, et al.
Publicado: (2022)

Overcoming resistance to immunotherapy by targeting GPR84 in myeloid-derived suppressor cells
por: Qin, Guohui, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_igfefrenm4aues35i122d69uhn